[144] Arteris, Inc. SEC Filing

Rhea-AI Filing Summary

Arteris, Inc. (AIP) submitted a Form 144 notifying the proposed sale of 2,057 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $18,163.31 and an approximate sale date of 09/04/2025. The shares were acquired as Restricted Stock Units on 09/01/2025. The filing also discloses multiple sales by the same account and related parties over the prior three months, including large 10b5-1 planned sales on 08/05/2025 and other dates. The filer attests there is no undisclosed material adverse information.

Positive

• Compliance disclosure: The filer provided a clear Form 144 notice including acquisition date, nature (RSUs), broker, and proposed sale date
• Transparency on prior sales: The filing lists recent 10b5-1 and other sales with amounts and gross proceeds

Negative

• Insider liquidity activity: Significant 10b5-1 sales occurred recently, notably 94,245 shares on 08/05/2025 and 50,000 shares by a related entity on 08/05/2025

Insights

Securities Analyst

TL;DR: Insider sold RSUs and disclosed multiple recent 10b5-1 sales; transaction sizes are documented but not shown as company-changing.

The Form 144 records a routine notice to sell newly vested restricted stock units (2,057 shares) via Morgan Stanley. The filing is transparent about acquisition date and proposed sale date, and it lists prior sales totaling sizeable lots (for example, 94,245 shares on 08/05/2025 and 50,000 shares on 08/05/2025 by a related entity) which may reflect planned liquidity rather than reactive selling. From a market-impact perspective, the individual proposed sale is small relative to the stated 42,649,917 shares outstanding, suggesting limited immediate dilution or market pressure. Monitor ongoing volume of 10b5-1 executions for trend changes.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 and 10b5-1 practices; attestation on lack of undisclosed material information is present.

The filing includes the required attestation that the seller is unaware of undisclosed material adverse facts and cites plan adoption/instruction dates where applicable. Listing of recent 10b5-1 transactions and seller identities (including BAYVIEW LEGACY, LLC and K. CHARLES JANAC) improves transparency about insider liquidity. There is no indication in this Form 144 of governance irregularities or undisclosed conflicts; the document performs its compliance function by providing transactional detail necessary for market oversight.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2057	18163.31	42649917	09/04/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2025	Restricted Stock Units	Issuer			2057	09/01/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
K. CHARLES JANAC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	09/02/2025	1246	1552516.00
10b5-1 Sales for K. CHARLES JANAC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	08/05/2025	94245	1271120.01
10b5-1 Sales for BAYVIEW LEGACY, LLC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	08/05/2025	50000	655995.00
10b5-1 Sales for K. CHARLES JANAC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	07/03/2025	11815	109230.86
K. CHARLES JANAC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	07/02/2025	7153	64322.64
10b5-1 Sales for K. CHARLES JANAC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	07/01/2025	2666	24238.74
10b5-1 Sales for BAYVIEW LEGACY, LLC 900 E. Hamilton Ave., Suite 300 Campbell CA 95008	Common	06/27/2025	18620	186585.43

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Arteris (AIP) Form 144 report?

The Form 144 notifies a proposed sale of 2,057 common shares (RSUs) with aggregate market value $18,163.31, to be sold via Morgan Stanley on 09/04/2025.

When were the shares acquired that are being sold under this Form 144?

The shares were acquired as Restricted Stock Units on 09/01/2025 and payment/date information is listed as 09/01/2025.

Has the filer sold other Arteris shares recently?

Yes. The filing lists multiple sales in the prior three months, including 94,245 shares on 08/05/2025 and 50,000 shares on 08/05/2025 (by BAYVIEW LEGACY, LLC).

Who is the broker handling the proposed sale?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

How many shares outstanding does Arteris report in this filing?

The filing reports 42,649,917 shares outstanding.